Please note that assistive links (commonly known as "skip to links") are used throughout this site. These links are not well-supported by some mobile devices. If you are encountering difficulty using these links, please navigate around these links, or access the site on a desktop browser.
Skip to the primary content of this page Skip to the footer of this page
Provident Healthcare Partners Provident Healthcare Partners

Q1 2024 Laboratory & Diagnostics Update

Provident Healthcare Partners
Skip to the end of the Expertise Menu

Q1 2024 Laboratory & Diagnostics Update

The Lab and diagnostics space continues to evolve amidst dynamic market forces and government scrutiny. After the COVID-19 pandemic there was a surge in the use of molecular testing and point-of-care solutions, underscoring a greater emphasis on accuracy and ease of use in testing methodologies. This ultimately led to significant utilization and earnings opportunity for these companies. Staffing shortages, notably for roles such as phlebotomists and lab technicians, posed operational challenges for laboratories, while inflationary pressures and regulatory burdens, such as rate depression, added to the complexity of maintaining healthy margins.

In recent quarters technological advancements fueled optimism, with a focus on early detection and individualized care driving investments in innovative testing solutions. Consolidation still seems beneficial as a means to enhance market positioning, access talent and technology, and capitalize on emerging opportunities.

To print and download the full Laboratory & Diagnostics Update report, please click below…

[holo_button icon=”/wp-content/uploads/2024/04/Q1-2024-Lab-Diagnostics-Newsletter.pdf”” color=”#003561″ target=”blank”]PRINT/DOWNLOAD[/holo_button]